These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 26718977)

  • 21. PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.
    Flatley E; Ang D; Warrick A; Beadling C; Corless CL; Troxell ML
    Hum Pathol; 2013 Jul; 44(7):1320-7. PubMed ID: 23352210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade.
    Mitra A; Raychaudhuri SK; Raychaudhuri SP
    Cytokine; 2012 Oct; 60(1):38-42. PubMed ID: 22840496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.
    Sun CH; Chang YH; Pan CC
    Histopathology; 2011 Jun; 58(7):1054-63. PubMed ID: 21707707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras.
    Wislez M; Spencer ML; Izzo JG; Juroske DM; Balhara K; Cody DD; Price RE; Hittelman WN; Wistuba II; Kurie JM
    Cancer Res; 2005 Apr; 65(8):3226-35. PubMed ID: 15833854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Correlation of Mutations and Expressions of Genes within the PI3K/Akt/mTOR Pathway in Breast Cancer-A Preliminary Study.
    Kołodziej P; Nicoś M; Krawczyk PA; Bogucki J; Karczmarczyk A; Zalewski D; Kubrak T; Kołodziej E; Makuch-Kocka A; Madej-Czerwonka B; Płachno BJ; Kocki J; Bogucka-Kocka A
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Juvenile papillomatosis of the breast (Swiss cheese disease) has frequent associations with PIK3CA and/or AKT1 mutations.
    Guillet C; Rechsteiner M; Bellini E; Choschzick M; Moskovszky L; Dedes K; Papassotiropoulos B; Varga Z
    Hum Pathol; 2020 Apr; 98():64-73. PubMed ID: 32088208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease.
    Chen S; Nakahara T; Uchi H; Takeuchi S; Takahara M; Kido M; Dugu L; Tu Y; Moroi Y; Furue M
    Br J Dermatol; 2009 Aug; 161(2):357-63. PubMed ID: 19438435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly.
    Lee JH; Huynh M; Silhavy JL; Kim S; Dixon-Salazar T; Heiberg A; Scott E; Bafna V; Hill KJ; Collazo A; Funari V; Russ C; Gabriel SB; Mathern GW; Gleeson JG
    Nat Genet; 2012 Jun; 44(8):941-5. PubMed ID: 22729223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence of chromosomal alterations in pure usual ductal hyperplasia as a breast carcinoma precursor.
    Xu S; Wei B; Zhang H; Qing M; Bu H
    Oncol Rep; 2008 Jun; 19(6):1469-75. PubMed ID: 18497952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
    Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
    Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC
    Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. "Immune TOR-opathies," a Novel Disease Entity in Clinical Immunology.
    Jung S; Gámez-Díaz L; Proietti M; Grimbacher B
    Front Immunol; 2018; 9():966. PubMed ID: 29867948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Everolimus-containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study.
    Chen Z; Zheng Y; Cao W; Zhang Y; Zhao Z; Wang G; Zhao J; Cai S; Shao X; Huang J; Ye W; Huang Y; Li W; Huang X; Wu H; Wang X; Yin Y
    Cancer Med; 2019 Sep; 8(12):5544-5553. PubMed ID: 31385461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
    Lim SM; Park HS; Kim S; Kim S; Ali SM; Greenbowe JR; Yang IS; Kwon NJ; Lee JL; Ryu MH; Ahn JH; Lee J; Lee MG; Kim HS; Kim H; Kim HR; Moon YW; Chung HC; Kim JH; Kang YK; Cho BC
    Oncotarget; 2016 Mar; 7(9):10547-56. PubMed ID: 26859683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in Fibfibroipose vascular anomaly (FAVA).
    Hori Y; Hirose K; Ozeki M; Hata K; Motooka D; Tahara S; Matsui T; Kohara M; Higashihara H; Ono Y; Tanaka K; Toyosawa S; Morii E
    Diagn Pathol; 2022 Jan; 17(1):19. PubMed ID: 35094709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dominant Splice Site Mutations in PIK3R1 Cause Hyper IgM Syndrome, Lymphadenopathy and Short Stature.
    Petrovski S; Parrott RE; Roberts JL; Huang H; Yang J; Gorentla B; Mousallem T; Wang E; Armstrong M; McHale D; MacIver NJ; Goldstein DB; Zhong XP; Buckley RH
    J Clin Immunol; 2016 Jul; 36(5):462-71. PubMed ID: 27076228
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Goto K; Maeda D; Kudo-Asabe Y; Hibiya T; Hayashi A; Fukayama M; Ohashi K; Goto A
    J Clin Pathol; 2017 May; 70(5):424-427. PubMed ID: 27742746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiplexed imaging reveals heterogeneity of PI3K/MAPK network signaling in breast lesions of known PIK3CA genotype.
    Jacob T; Gray JW; Troxell M; Vu TQ
    Breast Cancer Res Treat; 2016 Oct; 159(3):575-83. PubMed ID: 27581127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival.
    Pande M; Bondy ML; Do KA; Sahin AA; Ying J; Mills GB; Thompson PA; Brewster AM
    Breast Cancer Res Treat; 2014 Sep; 147(2):381-7. PubMed ID: 25108739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.